Monte Rosa Therapeutics/$GLUE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Monte Rosa Therapeutics
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
Ticker
$GLUE
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
142
ISIN
US61225M1027
Website
GLUE Metrics
BasicAdvanced
$247M
51.75
$0.08
1.52
-
Price and volume
Market cap
$247M
Beta
1.52
52-week high
$10.11
52-week low
$3.21
Average daily volume
596K
Financial strength
Current ratio
5.611
Quick ratio
5.53
Long term debt to equity
13.81
Total debt to equity
15.214
Management effectiveness
Return on assets (TTM)
-0.40%
Return on equity (TTM)
2.88%
Valuation
Price to earnings (TTM)
51.752
Price to revenue (TTM)
1.997
Price to book
0.9
Price to tangible book (TTM)
0.9
Price to free cash flow (TTM)
10.448
Growth
Revenue change (TTM)
14,889.38%
Earnings per share change (TTM)
-103.10%
3-year earnings per share growth (CAGR)
-68.00%
What the Analysts think about GLUE
Analyst ratings (Buy, Hold, Sell) for Monte Rosa Therapeutics stock.
GLUE Financial Performance
Revenues and expenses
GLUE Earnings Performance
Company profitability
GLUE News
AllArticlesVideos
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast Cancer
GlobeNewsWire·4 weeks ago
Monte Rosa Therapeutics, Inc. (GLUE) Q4 2024 Earnings Call Transcript
Seeking Alpha·2 months ago
Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Monte Rosa Therapeutics stock?
Monte Rosa Therapeutics (GLUE) has a market cap of $247M as of May 23, 2025.
What is the P/E ratio for Monte Rosa Therapeutics stock?
The price to earnings (P/E) ratio for Monte Rosa Therapeutics (GLUE) stock is 51.75 as of May 23, 2025.
Does Monte Rosa Therapeutics stock pay dividends?
No, Monte Rosa Therapeutics (GLUE) stock does not pay dividends to its shareholders as of May 23, 2025.
When is the next Monte Rosa Therapeutics dividend payment date?
Monte Rosa Therapeutics (GLUE) stock does not pay dividends to its shareholders.
What is the beta indicator for Monte Rosa Therapeutics?
Monte Rosa Therapeutics (GLUE) has a beta rating of 1.52. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.